Behavioural and biochemical evidence for interactions between Δ9-tetrahydrocannabinol and nicotine

British Journal of Pharmacology

Volumn 135, Issue 2, 2002, Pages 564-578

  Valjent, Emmanuel ^a,b   Mitchell, Jennifer M ^a   Besson, Marie Jo ^b   Caboche, Jocelyne ^b   Maldonado, Rafael ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b CNRS   (France)

Author keywords

c Fos; Nicotine; Place preference; Reward; Tolerance; Withdrawal; 9 tetrahydrocannabinol

Indexed keywords

CANNABIS; DRONABINOL; NICOTINE; PROTEIN C FOS;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CINGULATE GYRUS; CONTROLLED STUDY; DRUG ABUSE; DRUG DEPENDENCE; DRUG TOLERANCE; HYPOTHERMIA; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRIFORM CORTEX; STRIA TERMINALIS; THALAMUS MIDLINE NUCLEUS; TOBACCO; TRANQUILIZING ACTIVITY;

ANIMALS; BEHAVIOR, ADDICTIVE; BEHAVIOR, ANIMAL; BRAIN; DRUG INTERACTIONS; DRUG TOLERANCE; HALLUCINOGENS; MALE; MICE; NICOTINE; NICOTINIC AGONISTS; PROTO-ONCOGENE PROTEINS C-FOS; TETRAHYDROCANNABINOL;

EID: 0036180256     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704479     Document Type: Article

References (78)

1. Cannabinoid CB1 receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo
2. Cannabis: Pharmacology and toxicology in animals and humans
3. The effects of cannabinoids on the brain
4. Tolerance to the effect of delta-9-tetrahydrocannabinol in mice on intestinal motility, temperature and locomotor activity
5. Addiction, dopamine, and the molecular mechanisms of memory
6. Acetylcholine-mediated modulation of striatal function
7. Nicotinic excitation of rat ventral tegmental neurones in vitro studied by intracellular recording
8. Inhibition of hippocampal acetylcholine release after acute and repeated delta-9-tetrahydrocannabinol in rats
9. CB1 receptor antagonist precipitates withdrawal in mice exposed to delta-9-tetrahydrocannabinol
10. Nicotinic receptor function: New perspectives from knockout mice
11. The actions of nicotine and cocaine in a mouse model of anxiety
12. Molecular and cellular aspects of nicotine abuse
13. Pharmacology of some marijuana constituents and 2 heterocyclic analogues
14. Preproenkephalin mRNA and methionine-enkephalin content are increased in mouse striatum after treatment with nicotine
15. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats
16. Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice
17. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses
18. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra
19. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A
20. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors
21. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A
22. Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes
23. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices
24. Cannabinoid receptor localization in brain
25. Behavioral and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: Role of nicotinic receptors in the ventral tegmental area
26. Health aspects of cannabis
27. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol
28. Neuroscience of addiction
29. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice
30. Conditioned place preference induced by delta-9-tetrahydrocannabinol: Comparison with cocaine, morphine, and food reward
31. Spinal and supraspinal components of cannabinoid-induced antinociception
32. Opioid and cannabinoid modulation of precipitated withdrawal in delta-9-tetrahydrocannabinol and morphine-dependant mice
33. Nicotine receptors in the mammalian brain
34. Activation of multiple transcription factor genes by tertrahydrocannabinol in rat forebrain
35. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors
36. Delta-9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance
37. Modulation by fluoxetine of striatal dopamine release following delta-9-tetrahydrocannabinol: A microdialysis study in conscious rats
38. Nicotine binding sites and their localization in the central nervous system
39. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice
40. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits
41. Repeated administration of cocaine, nicotine and ethanol: Effects on preprodynorphin, preprotachykinin A and preproenkephalin mRNA expression in the dorsal and the ventral striatum of the rat
42. Distribution of preproenkephalin, preprotachykinin A, and preprodynorphin mRNAs in the rat nucleus accumbens: Effect of repeated administration of nicotine
43. Inducibility of c-Fos protein in visuo-motor system and limbic structures after acute and repeated administration of nicotine in the rat
44. Structure of a cannabinoid receptor and functional expression of the cloned cDNA
45. A comparison of delta-9-tetrahydrocannabinol and anandamide induced c-Fos expression in the rat forebrain
46. D2 dopamine receptors enable delta-9-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration
47. Genes and addiction
48. Pharmacological characterization of cannabinoids in the elevated plus maze
49. 7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents
50. Drugs which stimulate or facilitate central cholinergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice
51. 2 subunit are involved in the reinforcing properties of nicotine
52. Nicotine activates and desensitizes midbrain dopamine neurons
53. Interactions of delta-9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats
54. Induction of c-Fos immunostaining in the rat brain after the systemic administration of nicotine
55. Effect of cannabinoids on the turnover rate of acetylcholine in rat hippocampus, striatum and cortex
56. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
57. Nicotine-induced conditioned place preference and conditioned place aversion in mice
58. Activation of corticotropinreleasing factor in the limbic system during cannabinoid withdrawal
59. Downregulation of rat brain cannabinoid binding sites after chronic delta-9-tetrahydrocannabinol treatment
60. Corticotropin-releasing factor (CRF) antagonist [D-Phe12, N-le21,38, C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats
61. Cannabinoid-precipitated withdrawal: A time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression
62. Expression of Fos protein in various rat brain areas following acute nicotine and diazepam
63. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal
64. l opioid receptor mechanism
65. Effects of cannabinoids on levels of acetylcholine and choline and on turnover rate of acetylcholine in various regions of the mouse brain
66. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
67. A behavioural model to reveal place preference to delta-9-tetrahydrocannabinol in mice
68. Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties
69. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knockout mice
70. Delta-9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: Reduction in morphine withdrawal syndrome without change in rewarding effect
71. Reward and somatic changes during precipitated nicotine withdrawal in rats: Centrally and peripherally mediated effects
72. The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkelphalin levels in rats
73. Neurobiology of addiction
74. The paradox of nicotinic acetylcholine receptor upregulation by nicotine
75. 3 neuronal nicotinic acetylcholine receptor
76. 4 subunits of neuronal nicotinic acetylcholine receptors
77. Nicotine and heroin augment cocaine-induced dopamine overflow in nucleus accumbens
78. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice